Net Cash Provided by (Used in) Operating Activities of Revance Therapeutics, Inc. from 31 Dec 2012 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Revance Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Operating Activities in USD history and change rate from 31 Dec 2012 to 31 Mar 2024.
  • Revance Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2024 was $65,939,000, a 5.1% increase year-over-year.
  • Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was $216,575,000, a 12% decline from 2022.
  • Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $193,548,000, a 13% increase from 2021.
  • Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was $221,538,000, a 24% decline from 2020.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

Revance Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $65,939,000 +$3,561,000 +5.1% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q1 2023 $69,500,000 -$8,230,000 -13% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $61,270,000 +$13,485,000 +18% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q1 2021 $74,755,000 -$31,466,000 -73% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q1 2020 $43,289,000 -$31,875,000 -279% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q1 2019 $11,414,000 -$270,000 -2.4% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $11,144,000 +$10,048,000 +47% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q1 2017 $21,192,000 -$5,512,000 -35% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q1 2016 $15,680,000 -$2,654,000 -20% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q1 2015 $13,026,000 +$8,080,000 +38% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q1 2014 $21,106,000 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1

Revance Therapeutics, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $216,575,000 -$23,027,000 -12% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 $193,548,000 +$27,990,000 +13% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 $221,538,000 -$43,036,000 -24% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $178,502,000 -$72,341,000 -68% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $106,161,000 -$1,915,000 -1.8% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $104,246,000 -$8,904,000 -9.3% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $95,342,000 -$35,515,000 -59% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $59,827,000 -$4,158,000 -7.5% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $55,669,000 -$596,000 -1.1% 01 Jan 2015 31 Dec 2015 10-K 02 Mar 2018 2017 FY
2014 $55,073,000 -$7,315,000 -15% 01 Jan 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
2013 $47,758,000 -$8,844,000 -23% 01 Jan 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
2012 $38,914,000 01 Jan 2012 31 Dec 2012 10-K 04 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.